Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
  • Subscribe
Submit An Article

Latest Articles

  • Miners set to tumble as Commodities take a hit
    Miners set to tumble as Commodities take a hit
    • Market Update

  • Fastest growing allied health group welcomes 16 new Partners
    Fastest growing allied health group welcomes 16 new Partners
    • News

  • Ingenia delivers despite challenges, holiday business bounces back
    Ingenia delivers despite challenges, holiday business bounces back
    • News

  • Getting taught a lesson from Doctor Copper
    Getting taught a lesson from Doctor Copper
    • Opinion

  • Novatti eyes blockchain partners following US tour to promote AUDD at top crypto conference
    Novatti eyes blockchain partners following US tour to promote AUDD at top crypto conference
    • News

  • Cobram to drizzle 9.5 million litres of olive oil over dishes across Australia after exceptional harvest yield
    Cobram to drizzle 9.5 million litres of olive oil over dishes across Australia after exceptional harvest yield
    • News

  • Desperate millennial bails on drinks to stay up till 12.01am and lodge tax return
    Desperate millennial bails on drinks to stay up till 12.01am and lodge tax return
    • Satire

  • Market consolidate on GDP update
    Market consolidate on GDP update
    • Market Update

  • There are no scorpions involved in this company’s latest cancer drug
    There are no scorpions involved in this company’s latest cancer drug
    • News

  • AML3D engaged by ExxonMobil for 3D printed machinery
    AML3D engaged by ExxonMobil for 3D printed machinery
    • News

Alterity Therapeutics moves neuroprotective drug to Phase 2 trials

  • In News
  • June 2, 2022
  • Samantha Freidin
Alterity Therapeutics moves neuroprotective drug to Phase 2 trials

Seven to ten years. That’s how long someone diagnosed with multiple system atrophy (MSA) has to live from when symptoms first appear. The progressive disease results in the gradual functional decline of the body’s involuntary functions such as blood pressure, breathing, bladder function and motor control.

Often confused with Parkinson’s which is characterised by the progressive degradation of nerves that control movement, MSA affects the autonomic nervous system.

There is currently no evidence that MSA is genetic or caused by environmental factors, meaning this ‘sporadic’ rare disease can affect anyone.

With no specific treatment for MSA, doctors are resigned to managing symptoms to varying degrees of success. Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is developing a novel medication named ATH434 to reduce toxic levels of alpha-synuclein, a neuronal protein responsible for certain nerve cell functions. Alpha-synuclein accumulation is a pathological characteristic of MSA and plays a role in destruction of nerve cells. In theory, reducing accumulation of the protein in the brain will preserve function in patients.

The Drug has been granted Orphan Drug designation by the US Food and Drug Administration (FDA) and the European Commission (EC), and recently passed Phase 1 safety trials.

The Company is now furthering their work on ATH434, initiating a Phase 2 clinical trial for treatment of early stage MSA patients with enrolment now open in New Zealand. The randomised, double-blind and placebo controlled trial will evaluate the effect of the medication on protein levels in the brain and motor control in 60 patients. Patients will wear sensors that allow researchers to gather data on motor parameters. The trial will also further inform on the safety and pharmacokinetics of the drug.

ATH434 has potential applications in Parkinson’s Disease and other types of atypical parkinsonism as it inhibits the build up of proteins that cause neurodegeneration. With over 1 million people suffering from Parkinson’s in the US alone the treatment market is expected to exceed USD $11.5 billion by 2029- somewhat taking the sting out of having just one pipeline asset.

For the March quarter, Alterity reported a cash balance of $32 million

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Ingenia delivers despite challenges, holiday business bounces back - July 1, 2022
  • Cobram to drizzle 9.5 million litres of olive oil over dishes across Australia after exceptional harvest yield - June 30, 2022
  • There are no scorpions involved in this company’s latest cancer drug - June 29, 2022
  •  
  •  
  •  
  •  
  • alerity therapeutics
  • asx ath
  • ath434
  • biotech
  • neurodegeneration
  • parkinsons
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Ingenia delivers despite challenges, holiday business bounces back - July 1, 2022
  • Cobram to drizzle 9.5 million litres of olive oil over dishes across Australia after exceptional harvest yield - June 30, 2022
  • There are no scorpions involved in this company’s latest cancer drug - June 29, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Ingenia delivers despite challenges, holiday business bounces back - July 1, 2022
  • Cobram to drizzle 9.5 million litres of olive oil over dishes across Australia after exceptional harvest yield - June 30, 2022
  • There are no scorpions involved in this company’s latest cancer drug - June 29, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

Copyright © 2020 The Sentiment. All rights reserved.